

CERTIFICATE OF MAILING

I hereby certify that this paper or, if this paper is a transmittal letter, that every other paper or fee referred to therein is being deposited with the U.S. Postal Service as first class mail, in an envelope addressed to: Commissioner of Patents & Trademarks, Washington, DC 20231, on

(Date of Deposit)

Date

Name



11/10/94

October 20, 1994
10-20-94 *Hamitha Mann*

RECEIVED
OCT 28 1994
1010/16104-US4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): **WEINER, et al.**

Serial No.: **08/279,275**

Group Art Unit: **1813**

Filed: **July 22, 1994**

Examiner: **KIM, K**

For: **TREATMENT OF IMMUNE DISEASES BY ORAL
ADMINISTRATION OF AUTOANTIGENS**

October 19, 1994

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the disclosure duty under 37 CFR §§ 1.56 and 1.97, the documents listed on the accompanying Form PTO-1449 and copies¹ of the documents listed thereon. These documents

¹ To the extent that a document is listed and no copy of same is attached, then such document is not at the present time available to the undersigned or is available in the file of a parent application. If a listed document is not in the English language and an English translation is readily available, such translation is also attached; if translation is not attached it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then such equivalent patent is also cited on the attached form along with the corresponding foreign language patent and a connecting arrow indicated therebetween; if no such English language equivalent is cited, then none is known to the undersigned.

contain information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

- 1.* 4,804,745 02/14/89
- 2.* 5,075,112 12/24/91
3. WO 88/10120 12/29/88
4. WO 91/08760 06/27/91
- 5.* WO 92/06704 04/30/92
6. WO 92/06708 04/30/92
- 7.* WO 93/02699 02/18/93
8. WO 93/16724 09/02/93
- 9.* WO 93/21222 10/28/93
- 10.* Allegretta, M., et al., Science, 247:718-721, 1990.
- 11.* Avrillonis, K. and Boggs, J.M., J. Neuroimmunol. 35:201-10, 1991.
- 12.* Ben-Nun, A., et al., J. Immunol., 129:303-308, 1982.
- 13.* Burns, F.R., et al., J. Exp. Med., 169:27-39, 1989.
- 14.* Chen et al., Science 265:1237, 1994.
- 15.* Cremer, et al., J. Immunol. 87:2995, 1983.
- 16.* Eisenbarth, G.S., New Eng. J. Med. 314:1360-8, 1986.
- 17.* Englert, et al., Cell. Immunol. 87:357, 1984.
- 18.* Gaur et al., Science 258:1491-4, 1992.
- 19.* Harrison et al., J. Clin. Invest. 89:1161-5, 1992.
- 20.* Holoshitz, J. et al, J. Immunol. 131:2810, 1983
- 21.* Howell, M.D., et al., Science, 246:668-670, 1989.
22. Janeway, Nature 341:482-83, 1989.
- 23.* Khoury, S. J., et al., J. Exp. Med. 176:1355, 1992.
- 24.* Lane, I. William et al., Sharks Don't Get Cancer, Avery Publishing Group Inc., 1992, updated edition 1993.
- 25.* Lider et al., Ann. N. Y. Acad. Sci., pp. 267-273, 1986.
- 26.* Martin, R., et al., J. Immunol. 145:540-8, 1990.
- 27.* Martin, R., et al., J. of Exper. Med. 173:19-24, 1991.
- 28.* Martin, R., et al., J. Immunol. 148:1359-1366, 1992.
- 29.* Miller, A., et al., J. Exp. Med. 174:791, 1991.
- 30.* Miller, A., et al., Proc. Natl. Acad. Sci. USA 89:421, 1992.
- 31.* Miller, A., et al., J. Immunol. 151:7307-15, 1993.
- 32.* Miller, A., et al., J. Neuroimmunol. 46:73-82, 1993.
- 33.* Mori, et al., Diabetologia 29:244-7, 1986.
- 34.* Nussenblatt, R. B. et al., J. Immunol. 144:1689, 1990.
- 35.* Ota, K, et al., Nature, 346:183-7, 1990.
- 36.* Pette, M., et al., Proc. Natl. Acad. Sci., USA 87:7968-72, 1990.
- 37.* Pinals, R. S., et al., Arthritis Rheum. 24:1308, 1981.
- 38.* Rama, et al., Connective Tissue Research 12:111, 1984.
- 39.* Santos, L. M. B., et al., J. Immunol. 150:115A, 1993.
40. Schwartz, Ann. Rev. Immunol. 3:237-61, 1985.
- 41.* Sewel, K.L. and Trentham, D.E., The Lancet 341:283, 1993.
- 42.* Steinbrocker, O., et al., JAMA 140:659, 1949.
- 43.* Su, X., et al., J. Neuroimmunol. 34:181-190, 1991.
- 44.* Trentham, D. E., et al., Science 261:1727, 1993.
- 45.* Vandenbark, A.A., et al., Nature, 341:541-544, 1989.

X

- 46.* Weinblatt, M.E., et al., N. Eng. J. Med. 312:818, 1985.
- 47.^ Weiner et al., (Abstr) Neurology (Suppl. 1) 39:172, 1989.
- 48.^ Weiner, H. L., et al., Science 259:1321, 1993.
- 49.^ Whitacre, C. C., et al., J. Immunol. 147:2155, 1991.
- 50.♦ Wucherpfenning, K.W. et al., Science 248:1016-9, 1990.
- 51.♦ Zamvil, S. S., et al., Nature 324:258-260, 1986.
- 52.* Zhang, Z. J., et al., J. Immunol. 145:2489, 1990.
- 53.* Zhang, Z. J., et al., Proc. Natl. Acad. Sci. USA 88:10252 1991.
- 54.* Zhang, Z. J., et al., FASEB J. 6(5) A1693, 1992.

*These references are generally related towards the rheumatoid arthritis claims.

^These references are generally related towards diabetes mellitus claims.

♦These references are particularly relevant to the claims directed towards the use of Myelin Basic Protein fragments.

*These references are generally related towards the multiple sclerosis claims.

°These references are generally related towards other, unclaimed, autoimmune diseases.


In accordance with MPEP Sections 609 and 707.05(b) it is requested that each document cited (including any cited in applicants' specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449, so that it will appear on the face of the patent issuing on the present application, even if the Examiner does not consider it sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with.

The present Disclosure Statement is also being submitted in compliance with 37 CFR § 1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that

the cited documents represent the results of a complete search, and it is anticipated that the Examiner in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR §§ 1.104(a) and 1.106(b), and in the course of such search will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,


Adda C. Gogoris
Reg. No. 29,714
Attorney for Applicant(s)

DARBY & DARBY
805 Third Avenue
New York, New York 10022
(212) 527-7700